FAFrancesca Aweeka

Francesca Aweeka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francesca Aweeka has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Anura Jayewardene

    Department of Clinical Pharmacy, Drug Research Unit, School of Pharmacy, University of California, San Francisco, CA 94143-0622, USA

    2 shared publications
  • J Gambertoglio

    2 shared publications
  • John G. Gambertoglio

    Department of Clinical Pharmacy, Drug Research Unit, School of Pharmacy, University of California, San Francisco, CA 94143-0622, USA

    2 shared publications
  • S. Martin-Munley

    Univ. of Calif. Div. of Clinical Pharmacy San Francisco CA

    2 shared publications
  • Anne Hedman

    1 shared publication
  • Anura L. Jayewardene

    Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy & Life Science, Tokyo 192-03, Japan,1 and Drug Research Unit, Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, California 94143-06222

    1 shared publication

Latest Publications

  • High-Performance Liquid Chromatographic Determination of Ribavirin in Whole Blood To Assess Disposition in Erythrocytes

    by Masato Homma, Anura L. Jayewardene, John Gambertoglio, Francesca Aweeka

    Ribavirin is an antiviral agent used in the treatment of chronic hepatitis C virus infection. One of the limitations associated with the use of ribavirin is a reversible anemia caused by its accumulation in erythrocytes. Therefore, it is of interest to determine ribavirin levels in erythrocytes, as well as in plasma, as these measurements may be predictive of hematotoxicity. In the present study, we describe a high-performance liquid chromatographic (HPLC) assay for ribavirin in whole blood to estimate concentrations of free ribavirin and phosphorylated anabolites in erythrocytes. Since ribavirin exists primarily as phosphorylated anabolites (mono-, di-, and triphosphates) in erythrocytes, whole-blood extracts were initially dephosphorylated with acid phosphatase. The enzyme-treated samples were subjected to phenyl boronic acid column extraction for cleanup. The purified fraction was analyzed by reversed-phase HPLC, which was optimized for determination of ribavirin levels in whole blood. The recoveries of ribavirin from whole blood ranged from 63.1 to 90.7% at concentrations ranging from 1.67 to 40.0 μM. Intra- and interassay variations estimated at these concentrations were 3.2 to 10.4 and 4.7 to 11.7%, respectively. This method was used to quantitate ribavirin in samples both treated and untreated with acid phosphatase to estimate the extent of intracellular phosphorylation in erythrocytes. The method was also used to evaluate the effects of dipyridamole, a nucleoside transporter inhibitor, on ribavirin disposition in erythrocytes in in vitro experiments.


    • 15 August 1999
      • Vol. 21  (5) , 384-95

    Antiviral therapy for HIV patients with renal insufficiency.

    by D Jayasekara, F T Aweeka, R Rodriguez, R C Kalayjian, M H Humphreys, J G Gambertoglio

    Patients with HIV infection and HIV-related opportunistic infections are treated extensively with a spectrum of drugs. Introduction of new antiretroviral drugs, such as protease inhibitors and nonnucleoside reverse transcriptase inhibitors in addition to nucleoside reverse transcriptase inhibitors, has created exciting dimensions in treatment strategies. Renal dysfunction is also common in HIV-infected patients. Because some drugs used in HIV are primarily excreted unchanged by the kidney, dose adjustments are necessary in patients with renal insufficiency. Drugs such as foscarnet, cidofovir and adefovir are directly nephrotoxic, whereas acyclovir can crystallize in the kidneys, and indinavir may cause nephrolithiasis. This paper reviews the impact of renal insufficiency on pharmacokinetics of antiviral drugs used in HIV disease and discusses dosage recommendations needed to avoid toxicity. Finally, we summarize the effects of dialysis on removal of these drugs.


  • Effect of Renal Disease and Hemodialysis on Foscarnet Pharmacokinetics and Dosing Recommendations

    by Francesca T. Aweeka, Mark A. Jacobson, Sarah Martin-Munley, Anne Hedman, Patricia Schoenfeld, Rodney Omachi, Shirley Tsunoda, John G. Gambertoglio

    Foscarnet is an antiviral agent commonly used for managing patients with cytomegalovirus infection. Despite its clinical usefulness, foscarnet is associated with substantial adverse effects including nephrotoxicity. Moreover, foscarnet is primarily eliminated unchanged through the kidneys, thus requiring aggressive dose adjustment during kidney failure. To develop specific dosage guidelines, information on the disposition of this compound in patients with varying degrees of renal function and those requiring dialysis is essential. Twenty-six subjects were enrolled in this study and divided into five groups depending on their degree of renal dysfunction. Group 1 included subjects with normal renal function; group 5 included subjects requiring maintenance hemodialysis. Nondialysis study subjects received a single 60-mg/kg intravenous dose of foscarnet whereas hemodialysis subjects received two intravenous doses, separated by 1 week, to compare the effects of conventional and high-flux dialysis methods. Mean plasma clearance in control subjects averaged 2.1 ± 0.7 ml/minute/kg and declined proportionally with changing renal function as indicated by the regression equation: Equation [1] Mean half-life averaged 1.9 ± 0.1 hours in normal subjects and increased to a mean of 25 ± 19 hours in study subjects with severe impairment not on dialysis. Foscarnet dialysis clearance (based on dialysate recovery) averaged 183 ml/minute with conventional dialysis methods and 253 ml/minute during high-flux procedures, which resulted in removal of 37% and 38% of a dose for the two methods, respectively. These data indicate that substantial dosage adjustments must be made in renal failure patients. Therefore, a patient-specific dosage nomogram has been developed.


  • Failure to Detect Nelfinavir in the Cerebrospinal Fluid of HIV-1-Infected Patients With and Without AIDS Dementia Complex

    by Francesca Aweeka, Anura Jayewardene, Silvija Staprans, S. Eralp Bellibas, Brian Kearney, Patricia Lizak, Tatjana Novakovic-Agopian, Richard W. Price

    To assess the penetration of the HIV-1 protease inhibitor, nelfinavir, into cerebrospinal fluid (CSF). Nelfinavir, a commonly used HIV-1 protease inhibitor (PI), is highly effective for reducing plasma viral load. It is deployed clinically in combination with other antiretroviral agents, including nucleoside and nonnucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs). Despite its potency based on plasma HIV-1 RNA results, its effectiveness in reducing HIV-1 RNA levels (i.e., viral load) in the central nervous system (CNS) is less certain. We sampled the CSF as a surrogate for brain because this fluid also is separated from the blood by a barrier to free diffusion, the blood-CSF barrier (BCB), which shares properties with the blood-brain barrier (BBB). These studies of nelfinavir CSF pharmacokinetics exploited the multiple CSF samples derived from individual study subjects who were enrolled in studies the primary objective of which was to compare viral kinetics in CSF and blood in response to antiviral therapy. Six study subjects, four with and two without AIDS dementia complex, underwent multiple lumbar punctures (LP). Intervals of CSF sampling after drug dosing were varied (from 0.48 hours to 10.3 hours after nelfinavir administration) to quantitate nelfinavir concentrations throughout the steady-state dosing interval. In four study subjects, CSF sampling was accompanied by assessment of nelfinavir levels in plasma before and after LP, whereas in the other two subjects, a single plasma sample was obtained before or after the LP. In total, 25 CSF samples were analyzed. Nelfinavir concentrations in CSF and plasma were determined using an high-performance liquid chromatography (HPLC) method with a limit of quantitation of 25 and 50 ng/ml, respectively. Plasma concentrations before and after LP averaged 2420 ± 1365 ng/ml and 2528 ± 1132 ng/ml, respectively. Nelfinavir was not detected in any of the CSF samples and levels >25 ng/ml were not present in the CSF. Thus, standard therapy with nelfinavir does not result in CSF drug concentrations at or exceeding the IC95 level for most HIV-1 isolates. However, study subjects with high CSF viral loads experienced a marked reduction in the context of the combination-drug regimen including nelfinavir with two subjects showing a comparable CSF response with that in plasma. Nelfinavir does not appreciably penetrate into the CSF. The clinical importance of this observation is not certain, in that in four study subjects who initiated nelfinavir in combination with other antiretroviral therapy, a comparable degree of viral suppression was obtained in both the CSF and the blood when sampled 4 weeks or later after initiating therapy.


    • 1 February 1989
      • Vol. 21, 1718-21

    Interleukin-2 and immunoglobulin increases with H2-antagonists in humans.

    by F Aweeka, P Lizak, M Garovoy, W Amend, J Birnbaum, M Gumbert, J Gambertoglio

    • 1 October 1988
      • Vol. 158  (4) , 862-5

    Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.

    by M A Jacobson, S Crowe, J Levy, F Aweeka, J Gambertoglio, N McManus, J Mills